Home to only 1.2% of the world’s population, Germany participates in approximately 7% of world’s clinical trials. The country is the most populous in Europe, but Germany’s involvement in clinical trials goes beyond its demographics. Its strong medical tradition, long history of leadership in clinical research, and broad governmental support and funding for biomedical sciences has made the country a desirable location for pharmaceutical research and development (R&D), production, and sales. Germany’s relationship with clinical research includes many positive factors.
Germany has a strong medical tradition with a long history of excellence in biomedical research among individuals, universities, institutes, and associations.
Many pharmaceutical companies, both large and small, have facilities in Germany, encouraged by the country’s high medical, technical and ethical standards, standardized and reliable approval processes for clinical trials, and relatively short timelines for study start up.
Since 2004, clinical trials must be approved in Germany by the respective competent federal higher authority (depending on the type of product, either the BfArM or the PEI). This approval is required in addition to the favorable opinion from the competent Ethics Committee.
CRU-GLOBAL local affiliate is: CRU Global GmbH in Frankfurt am Main, established in 2019.
Currently Phase II-IV outpatient studies in the field of internal medicine, oncology, gynecology, gastroenterology, ophtalmology, dermatology and rheumatology.